amonafide

Small moleculeexperimental

Amonafide was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator. — Wikipedia

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started Mar 1, 2004 (NCT00087854)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCN1C(=O)c2cccc3cc(N)cc(c23)C1=O
Mol. weight
283.33 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1h-benz(de)isoquinoline-1,3(2h)-dione, 5-amino-2-(2-(dimethylamino)ethyl)-
  • 5-amino-2-(2-dimethylaminoethyl)benzo(de)isoquinolin-1,3-dione
  • amonafide
  • amonafide
  • amonafide
  • amonafide
  • amonafide
  • amonafide l-malate
  • amonafide l-malate
  • as-1413
  • as-1413
  • benzisoquinolinedione
  • fa 142
  • m-fa 142
  • m-fa-142
  • mfa 142
  • mfa-142
  • nafidimide
  • nsc 308847
  • nsc-308847

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01066494Phase 2Jan 1, 2010Antisoma Research
NCT00715637Phase 3Jun 1, 2007Antisoma Research
NCT00273884Phase 2Aug 1, 2005North Shore Hospital, New Zealand, Xanthus Pharmaceuticals, Inc.
NCT00087854Phase 1/Phase 2 (Phase 2)Mar 1, 2004Johns Hopkins University, Xanthus Pharmaceuticals, Inc.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Antisoma ResearchFor profit2222007
Xanthus Pharmaceuticals, Inc.For profit2212004
Johns Hopkins UniversityAcademic/Hospital1012004
North Shore Hospital, New ZealandAcademic/Hospital1012005
4 organizations
Page 1 / 1